Application of forsythiaside A in preparation of medicine and method for screening active components in medicine
By screening and evaluating the Aβ aggregation inhibition effect of forsythia esterside A, the problem of insufficient effect of existing Alzheimer's disease therapeutic agents was solved, effective Aβ aggregation inhibition and decomposition were achieved, and it demonstrated its in Alzheimer's disease disease Potential in therapy.
Patent Information
- Application Number
- CN202410997047.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-24
- Publication Date
- 2024-11-08
AI Technical Summary
The effect of the existing Alzheimer's disease (Aβ aggregation inhibitor) needs to be improved, and there is a lack of new small molecule inhibitors as alternative active components, so there is room for improvement in the screening method.
Forsythia esterside A is used as the active component in the drug. By screening natural molecules in the database, using Gold software for molecular docking simulation scores, combined with sulfur fractin T kinetics, dynamic light scattering, circular dichromatography and cytotoxicity tests. Potential active components with high-efficiency Aβ aggregation inhibition effect were screened.
Forsythia esterside A can not only inhibit the aggregation of Aβ and decompose preformed Aβ fibrils, but also significantly improve drug activity and have potential for the treatment of Alzheimer's disease and cognitive impairment diseases.
Smart Images

Figure CN118903162A_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the field of medicinal chemistry, and in particular, to the use of forsythiaside A in preparing drugs and a method for screening active components in drugs. Background Art
[0002] Alzheimer's disease (AD) remains a major threat to human health. In 2019, it was reported that 55 million people worldwide suffered from dementia, and this number is expected to increase to 139 million by 2050. Based on the amyloid cascade hypothesis that Aβ aggregation is the main cause of AD, eliminating Aβ aggregates from the patient's brain and inhibiting Aβ aggregation appear to be methods for preventing and treating Alzheimer's disease.
[0003] At present, inhibitors that inhibit Aβ aggregation include small molecules, peptides, macrocycles, and nanoparticles. Small molecule inhibitors have excellent drugability and have therefore received widespread attention. Although many small molecule inhibitors have been developed, no successful clinical trials have been found, indicating that new and effective inhibitory molecules are needed as alternative active components of small molecule inhibitors.
[0004] Therefore, current methods for screening Aβ aggregation inhibitors and active components in drugs still need to be improved. Summary of the invention
[0005] The present application provides a use of forsythiaside A in preparing a drug and a method for screening active components in a drug, so as to solve or alleviate one or more technical problems in the related art.
[0006] As one aspect of the present application, the present application proposes the use of forsythiaside A in the preparation of a drug for preventing and / or alleviating the insoluble accumulation of Aβ protein.
[0007] As another aspect of the present application, the present application proposes the use of forsythiaside A in preparing an inhibitor for inhibiting Aβ aggregation.
[0008] As another aspect of the present application, the present application proposes the use of Forsythiaside A in the preparation of a drug for preventing and / or treating diseases of cognitive impairment.
[0009] As another aspect of the present application, the present application proposes the use of Forsythiaside A in the preparation of a drug for preventing and / or treating Alzheimer's disease.
[0010] As another aspect of the present application, the present application proposes a method for screening active components in drugs. The method comprises: retrieving and screening natural molecules in a database, wherein the molecular weight of the natural molecules is not greater than 2000; performing molecular docking of the natural molecules with Aβ fiber targets by Gold software, and performing simulation scoring on the molecular docking, selecting the natural molecules with scores exceeding 80 to form a potential active component set; performing an Aβ aggregation inhibition effect test on the molecules of the potential active component set, and determining one or more active components, wherein the Aβ aggregation inhibition effect test includes at least one of a thioflavin T kinetic test, an Aβ aggregate dynamic light scattering test, and a circular dichroism test, as well as a cytotoxicity test and a nematode lifespan test, and the drug is the drug or inhibitor described above.
[0011] According to an embodiment of the present application, the database includes the Selleck database, and the searching and screening includes selecting natural products of traditional Chinese medicine in the database.
[0012] According to an embodiment of the present application, the simulation scoring of the molecular docking includes: predicting the binding activity of the natural molecule and the target through electric field force analysis and performing a simulation scoring, the target is a target related to inhibition and / or decomposition of Aβ aggregates, the target includes the Aβ fiber end and the Aβ fiber surface, and the simulation scoring includes analyzing the characteristics of the natural molecule and the target, and simulating the binding mode of the natural molecule and the target.
[0013] According to an embodiment of the present application, the potential active component set includes: itraconazole, thymopentin, diammonium glycyrrhizinate, forsythiaside B, angloside C, barisenoside A, neferine, forsythiaside A, and steviol glycosides.
[0014] According to an embodiment of the present application, the Aβ aggregation inhibition effect test includes:
[0015] (1) dissolving the natural molecules in the potential active component set in DMSO to prepare solutions with a concentration of 5-15 mM, and performing thioflavin T kinetic tests on them respectively;
[0016] (2) selecting the natural molecule with the largest reduction in Thioflavin T signal in the Thioflavin T kinetic test, and continuing to perform Aβ40 aggregate dynamic light scattering test and circular dichroism test;
[0017] (3) If the Aβ40 aggregate dynamic light scattering test and circular dichroism test results of the natural molecule meet the standards, the cytotoxicity test and nematode lifespan test are continued; if one of the Aβ40 aggregate dynamic light scattering test and circular dichroism test results do not meet the standards, the natural molecule with the second largest reduction in the Thioflavin T signal in the Thioflavin T kinetic test is selected, and the Aβ40 aggregate dynamic light scattering test and circular dichroism test are continued;
[0018] (4) If the cytotoxicity test and the nematode lifespan test meet the standards, the natural molecule is determined to be the active component. If the cytotoxicity test does not meet the standards, the natural molecule with the second largest reduction in the thioflavin T signal in the thioflavin T kinetic test is selected to continue the test in step (2) until the Aβ40 aggregate dynamic light scattering test and the circular dichroism test of the selected natural molecule meet the standards and the cytotoxicity test meets the standards.
[0019] According to the embodiments of the present application, the standard for the dynamic light scattering test of Aβ40 aggregates to meet the standard is: after incubation treatment under the conditions of the presence of the natural molecule, the particle size of the particles of the Aβ40 aggregates is reduced by not less than 80%; the standard for the circular dichroism test to meet the standard is: after incubation treatment under the conditions of the presence of the natural molecule, the absolute value of the peak intensity of the characteristic peak of the circular dichroism spectrum of the Aβ40 aggregates is reduced by more than 50%; the standard for the cytotoxicity test to meet the standard is: after the Aβ40 solution added with the natural molecule and incubated is co-incubated with N2a cells, the survival rate of N2a cells is not less than 70%; the standard for the nematode lifespan test to meet the standard is: after the Aβ40 solution added with the natural molecule and incubated is co-incubated with nematodes, the median lifespan of the nematodes increases by not less than 5 days. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] In the accompanying drawings, unless otherwise specified, the same reference numerals throughout the multiple drawings represent the same or similar parts or elements. These drawings are not necessarily drawn to scale. It should be understood that these drawings only depict some embodiments according to the present disclosure and should not be regarded as limiting the scope of the present disclosure.
[0021] Figure 1 The thioflavin endpoint method screening result of the natural product according to one embodiment of the present disclosure;
[0022] Figure 2 is a kinetic test result of Thioflavin T of Forsythiaside A according to one embodiment of the present disclosure;
[0023] Figure 3 The dynamic light scattering test results and circular dichroism spectrum test results of forsythiaside A inhibiting Aβ aggregation and disaggregating Aβ fibers according to one embodiment of the present disclosure;
[0024] Figure 4 is a cytotoxicity test result according to one embodiment of the present disclosure;
[0025] Figure 5 This is the experimental test result of forsythiaside A extending the life span of AD model nematodes according to one embodiment of the present disclosure;
[0026] Figure 6 The dot blot test results of forsythiaside A inhibiting Aβ aggregation and disaggregating Aβ fibers according to one embodiment of the present disclosure. DETAILED DESCRIPTION
[0027] In the following, only some exemplary embodiments are briefly described. As those skilled in the art will appreciate, the described embodiments may be modified in various ways without departing from the spirit or scope of the present disclosure, and different embodiments may be combined arbitrarily without conflict. Therefore, the drawings and descriptions are considered to be illustrative in nature and not restrictive.
[0028] As mentioned above, the inhibitors or drugs that currently have the effect of inhibiting Aβ aggregation still have problems such as the effect needs to be improved and the types of potential active drug components need to be expanded. Among the molecules or particles that have been proven to have a certain Aβ aggregation inhibitory effect, small molecule drug active components have better potential to pass clinical trials. Considering that 30.6% of the small molecule drugs approved by the FDA from 1981 to 2019 are natural products or natural product derivatives, strengthening the screening of small molecules of natural products of traditional Chinese medicine is expected to find new and effective natural small molecule Aβ aggregation inhibitors with great therapeutic potential.
[0029] In the present invention, we used a specific method for screening active components to virtually screen 1561 natural molecules, and selected and confirmed that a variety of small molecules have the potential to become new Aβ aggregation inhibitors. Among them, Forsythiaside A has the most outstanding effect. Its thioflavin T kinetics, dynamic light scattering, circular dichroism spectrum, dot blot, nematode lifespan experiment and cell experiment results show that Forsythiaside A can not only inhibit the aggregation and cytotoxicity of Aβ, but also decompose preformed Aβ fibrils.
[0030] In view of this, in one aspect of the present application, the present application proposes the use of forsythiaside A in the preparation of a drug for preventing and / or alleviating the insoluble accumulation of Aβ protein.
[0031] As another aspect of the present application, the present application proposes the use of forsythiaside A in preparing an inhibitor for inhibiting Aβ40 aggregation.
[0032] As another aspect of the present application, the present application proposes the use of Forsythiaside A in the preparation of a drug for preventing and / or treating diseases of cognitive impairment.
[0033] As another aspect of the present application, the present application proposes the use of Forsythiaside A in the preparation of a drug for preventing and / or treating Alzheimer's disease.
[0034] In the present application, the dosage form of the above-mentioned drugs and / or inhibitors is not particularly limited, for example, it can be tablets, injections, capsules, granules, etc. The content of the active ingredient in the drug, that is, forsythiaside A, is not particularly limited.
[0035] As another aspect of the present application, the present application proposes a method for screening active components in drugs. The method screens natural molecules in a database, selects small molecule natural product molecules for molecular docking and simulates scoring. By adjusting the simulation scoring process, the natural molecules screened out with a score of more than 80 points can have good activity data. Therefore, the method can easily select a potential active component set from a large number of molecules, and subsequently further test and verify the potential active component set to screen out natural molecule products with good drug activity.
[0036] Specifically, the method includes: retrieving and screening natural molecules in a database, wherein the molecular weight of the natural molecules is not greater than 2000; performing molecular docking on the natural molecules through Gold software, and performing simulation scoring on the molecular docking, and selecting the natural molecules with scores exceeding 80 to form a potential active component set; performing an Aβ aggregation inhibition effect test on the molecules of the potential active component set to determine one or more active components, wherein the Aβ aggregation inhibition effect test includes at least one of a thioflavin T kinetic test, an Aβ40 aggregate dynamic light scattering test, and a circular dichroism test, and a cytotoxicity test, and the drug is the drug or inhibitor described above.
[0037] According to the embodiments of the present application, the selection of the database is not particularly limited, and those skilled in the art may select a commercial database for the first step of retrieval and screening according to actual conditions. For example, in one embodiment, the database may include the Selleck database.
[0038] In this method, the natural products of Chinese medicinal materials in the database can be first searched and screened to select molecules with a molecular weight of no more than 2000, for example, molecules with a molecular weight of 300-1800 can be screened out as alternatives.
[0039] Subsequently, the selected candidate molecules can be subjected to molecular docking. Molecular docking of candidate molecules is used to evaluate the coordination mode between drug small molecules (ligands) and the action targets of receptors, and is an effective simulation method. Specifically, molecular docking can first process the ligand structure file, such as structural transformation, optimization, etc. Subsequently, the receptor is structurally modeled, and the active site of the receptor is predicted to determine the docking pocket position. And according to the size of the drug small molecule and the position of the docking pocket, the docking box parameters are set. The docking box parameters may include the size and shape of the docking box. Subsequently, the docking parameters and docking accuracy can be set as needed. In some embodiments, the candidate molecules with smaller molecular weight and smaller calculation amount can be first selected to perform molecular docking pre-calculation. If the data obtained have good consistency, the docking box can be set according to the parameters, and molecular docking of other candidate molecules can be performed.
[0040] For example, in this step, the properties and characteristics of candidate molecules and targets related to Aβ40 aggregates, as well as their interactions, can be analyzed to achieve screening of candidate molecules. By analyzing the properties and characteristics of candidate molecules and targets related to Aβ40 aggregates through electric field force, the binding activity of the natural molecule and the target can be predicted, thereby estimating its activity as a drug, and based on molecular docking, multiple candidate molecules can be simulated and scored. Specifically, the targets in this step can be targets related to the inhibition and / or decomposition of Aβ40 aggregates, including but not limited to the ends of Aβ fibers and the surfaces of Aβ fibers.
[0041] Subsequently, the molecular docking results of the candidate molecules can be simulated and scored. Molecules with a score greater than 80 are selected to form a set of potential active components. When the score is greater than 80, it means that the binding activity between the candidate molecule and the binding site is high, and there is reason to obtain good drug activity results in subsequent effect verification, thereby reducing the number of trial and error times in repeated Aβ aggregation inhibition effect tests, which is conducive to saving the time cost and drug cost of the method.
[0042] According to the embodiments of the present application, the potential active component set includes: itraconazole, thymopentin, diammonium glycyrrhizinate, forsythiaside B, angloside C, barisonoside A, neferine, forsythiaside A, and steviol glycoside. The natural molecules contained in the above-mentioned potential active component set all have a certain effect of inhibiting or decomposing Aβ aggregation, which can improve the success rate of subsequent effect tests to screen out components with good drug activity. In addition, the potential active component set screened out using the aforementioned steps can have an appropriate number of natural molecules, which will not greatly increase the workload of the subsequent Aβ aggregation inhibition effect, nor will it be difficult to screen out good natural molecules for the subsequent Aβ aggregation inhibition effect due to too few natural molecules.
[0043] In some embodiments, in order to further optimize the obtained set of potential active components, the method may also include performing a thioflavin endpoint screening operation on the candidate molecules with a score of more than 80 points. Specifically, all the screened molecules are dissolved in DMSO (dimethyl sulfoxide) to obtain a 10mM solution. Then, 5μM Aβ40, 20μM thioflavin T and 50μM molecules are used to perform thioflavin T kinetic analysis in PBS buffer. Finally, based on the excellent fluorescence intensity and water solubility of thioflavin T, the potential active components are further screened. Figure 1 It is a natural product small molecule screened by the thioflavin endpoint method.
[0044] According to the embodiments of the present application, the natural molecules of the obtained potential active component set can then be tested for the Aβ aggregation inhibition effect. The test may include the following steps:
[0045] (1) Dissolve the natural molecules in the potential active component set in dimethyl sulfoxide (DMSO) to prepare solutions with a concentration of 5-15 mM, and perform kinetic tests on Thioflavin T. Specifically, the concentration of the DMSO solution of the natural molecule can be 10 mM, and the solution can be used as a standard solution, and the concentration can be diluted to a suitable concentration in subsequent tests.
[0046] Specifically, the Thioflavin T kinetic test may include: first dissolving the purchased Aβ40 powder to a concentration of 0.5 mg / mL using 1% ammonium hydroxide. The dissolved Aβ is lyophilized to produce Aβ monomers and stored at -80°C. Prior to the Thioflavin T kinetic test, the lyophilized Aβ is re-dissolved using 6 mM NaOH to a final concentration of 100 μM. The 100 μM Aβ40 solution is sonicated to ensure its monomeric state and then immediately added to the plate for Thioflavin T (ThT) kinetic analysis.
[0047] Natural molecules such as forsythiaside A were dissolved in water to obtain a 10mM stock solution. The final sample for the kinetic assay of Thioflavin T contained 0.5wt% water, 5wt% 6mM NaOH and 94.5wt% PBS, which contained 5μMAβ40, 20μM Thioflavin T and different concentrations of the natural molecules to be tested. The samples were added to a 96-well plate, incubated at 37°C, continuously shaken at 850-870rpm, and the fluorescence signal was monitored every 6 minutes using a Tecan Infinite M200PRO microplate reader. The excitation wavelength during detection was 440nm and the emission wavelength was 480nm. Each group was repeated 4 times, and the kinetic assay of Thioflavin T was repeated 3 times.
[0048] (2) Selecting the natural molecule with the greatest reduction in Thioflavin T signal in the Thioflavin T kinetic test, and continuing to perform Aβ40 aggregate dynamic light scattering test and circular dichroism test.
[0049] In this step, dynamic light scattering and circular dichroism tests can be used to further verify the inhibitory effect of the native molecule. Dynamic light scattering experiments can assess the size of Aβ40 aggregates in the absence or presence of the native molecule.
[0050] like Figure 3 As shown, specifically, 5 μM Aβ40 can be selected to be incubated alone at 37°C and 1100 rpm for two days, and the particle size can be observed. At this time, particles of about 1000 nm can be observed. This group of experiments can be used as a control group. Subsequently, when 5 μM Aβ40 is incubated with 10 μM natural molecules, the size of the particles is observed. In the experimental group incubated with natural molecules, the group with a particle size reduction of more than 80% can be judged as passing the test.
[0051] For example, in the experimental group co-incubated with forsythiaside, almost no particles larger than 100 nm were found after the end of incubation, which indicates that forsythiaside A effectively inhibits the formation of larger Aβ40 aggregates.
[0052] The circular dichroism spectroscopy test may include: using a NaF buffer solution composed of 10 mM sodium phosphate and 150 mM NaF (pH 7.4) as a solution, and recording the CD spectrum using a Chirascan circular dichroism spectrometer. The natural molecule to be tested is dissolved in a NaF buffer at a concentration of 1 mM. 100 μM Aβ40 in 6 mM NaOH is diluted to 10 μM in NaF buffer and continuously shaken at 1000-1200 rpm in a metal bath at 37°C, incubated for 2 days in the presence or absence of different concentrations of natural molecules for circular dichroism spectroscopy analysis. The secondary structure of Aβ40 aggregates in the absence or presence of different concentrations of natural molecules is analyzed by circular dichroism spectroscopy. In order to obtain a strong primary color spectral signal, a quartz cuvette can be used. Preformed 10 μM Aβ40 fibrils can also be incubated with 10 μM or 50 μM of natural molecules for 2 days to examine the decomposition effect of natural molecules on Aβ40 fibrils. The change in the intensity of the characteristic peak of the circular dichroism spectrum can evaluate the change in the structure of Aβ40 aggregates and / or Aβ40 fibrils, and thus can be used to evaluate the degradation effect of natural molecules on Aβ40 aggregates and / or Aβ40 fibrils. For example, newly dissolved Aβ40 shows a negative peak at around 198nm, while Aβ40 fibrils have a typical β-folded structure with a negative peak at around 218nm. Therefore, the peak intensity at the above position can be used to judge the change in the number of folded structures in the system. For the experimental group incubated with natural molecules, the group whose absolute value of the intensity of the corresponding characteristic peak decreased by more than 50% can be judged as passing the test.
[0053] If the Aβ40 aggregate dynamic light scattering test and circular dichroism test of the natural molecule both pass the test, then the natural molecule is selected to continue the test in step (3). If one of the Aβ40 aggregate dynamic light scattering test and circular dichroism test of the natural molecule does not meet the above test standards, then the natural molecule with the second largest reduction in the Thioflavin T signal in the Thioflavin T kinetic test obtained in the previous step, i.e., step (1), is selected to perform the Aβ40 aggregate dynamic light scattering test and circular dichroism test in step (2).
[0054] (3) Carry out the cytotoxicity test
[0055] According to the embodiments of the present application, in this step, if the natural molecules screened out meet the standards in the Aβ40 aggregate dynamic light scattering test and the circular dichroism test in step (2), a cytotoxicity test is performed to further evaluate the potential of the natural molecules as pharmaceutical active substances:
[0056] Specifically, 5 μM Aβ40 was incubated for 1 day in the absence or different concentrations of natural molecules. The sample was then diluted 10 times with serum-free medium and incubated with N2a cells for 24 hours. The cell viability of different groups was determined using a cell counting kit-8 (CCK8), and the cytotoxicity test results of the natural molecules were judged by evaluating the degree of improvement in cell survival rate. If the cell survival rate is 70% or above after the diluted sample is incubated with N2a cells for 24 hours, it can be determined that the cytotoxicity test meets the standard. If the cytotoxicity test of the natural molecule does not meet the standard, the natural molecule with the second largest reduction in the thioflavin T signal in the thioflavin T kinetic test in step (1) is selected to continue repeating the test of step (2).
[0057] Hereinafter, the embodiments of the present application will be described. The embodiments described below are exemplary and are only used to explain the present application, and should not be construed as limiting the present application. If no specific techniques or conditions are indicated in the embodiments, the techniques or conditions described in the literature in this area or the product specifications are used. If the manufacturer is not indicated in the reagents or instruments used, they are all conventional products that can be obtained commercially.
[0058] Acquisition of a collection of potential active components
[0059] First, 1561 natural molecules were retrieved from Selleck, and then molecular docking was performed using Gold Suite 5.3.
[0060] Specifically, before molecular docking, the structures of 1561 traditional Chinese medicine molecules can be obtained from the Selleck official website, and these molecular structures can be pre-processed using RDKit, including hydrogenation, generation of 3D structure and energy minimization. The Aβ40 fiber structure with two-fold symmetry (PDB code: 2LMN) was obtained from the PDB database as the receptor structure. The fibril ends of the 2LMN structure were divided into eight different grid boxes for docking. Molecular docking was performed using Gold Suite 5.3 and the ChemPLP scoring function. The general algorithm was set to "automatic", allowing each molecule to retain up to 10 poses, and other parameters remained at the default values. Subsequently, the results were sorted according to the ChemPLP score and visually inspected to identify compounds with enhanced binding affinity to Aβ fibrils.
[0061] Natural molecules with a simulation score of more than 80 were screened out. The screened molecules were dissolved in DMSO (dimethyl sulfoxide) to prepare a natural molecule stock solution with a concentration of 10 mM.
[0062] The screened potential active components include itraconazole (Itra), thymopentin (Thy), diammonium glycyrrhizinate (Diam), forsythiaside B (ForB), angoside C (AngC), parisonoside A (Pari), neferine (Nef), forsythiaside A (ForA), and steviol glycoside (Ste).
[0063] Screening of natural product molecules
[0064] Thioflavin T kinetic analysis was performed in PBS buffer using 5 μM Aβ40, 20 μM Thioflavin T, and natural molecule solution diluted to 50 μM. Finally, based on the excellent fluorescence intensity and water solubility of Thioflavin T, the natural molecule was subjected to Thioflavin T kinetic analysis, thereby realizing the screening of natural molecules in the potential active component collection by the Thioflavin T endpoint method.
[0065] Figure 1 For the natural product small molecules screened by the thioflavin endpoint method, the ThT signal intensity after 5μM Aβ40 aggregation alone reached the platform was defined as 100%, and the signal of 20μM thioflavin T was defined as 0%. The endpoint ThT signals of other groups were normalized according to this rule. Figure 1 It can be seen that Figure 1 The ordinate in the figure is the relative signal intensity, Relative intensity (%), among which the signal reduction degree of forsythiaside A and thioflavin T is the largest.
[0066] The purchased Aβ40 powder was dissolved with 1% ammonium hydroxide to obtain a solution with a concentration of 0.5 mg / mL. The dissolved Aβ was lyophilized to produce Aβ monomers and stored at -80°C. Before performing Thioflavin T kinetics, the lyophilized Aβ was re-dissolved with 6 mM NaOH to a final concentration of 100 μM. The 100 μM Aβ40 solution was sonicated to ensure its monomeric state and then immediately added to the multi-well plate for ThT kinetics analysis.
[0067] The natural molecule forsythiaside A was dissolved in water to obtain a 10mM stock solution. The final sample for the kinetic assay of Thioflavin T contained 0.5% water, 5% 6mM NaOH and 94.5% PBS, and the test samples contained 5μM Aβ40, 20μM Thioflavin T and 2.5 (1:0.5), 5 (1:1), 10 (1:2), 25 (1:5), 50μM (1:10) of Forsythiaside A. The samples were added to Corning 360396-well plates, incubated at 37°C, continuously shaken at 886.9rpm, and the fluorescence signal was monitored every 6 minutes using a Tecan Infinite M200 PRO microplate reader with an excitation wavelength of 440nm and an emission wavelength of 480nm. Each group was repeated 4 times, and the kinetic assay of Thioflavin T was repeated 3 times.
[0068] Figure 2 The ordinate is the normalized signal intensity (Normalized intensity, %), and the abscissa is the time. Figure 2 (A) in the figure is the kinetic test result of Thioflavin T on the inhibition of Aβ aggregation by different concentrations of Forsythiaside A. As the concentration of Forsythiaside A added increases, the intensity of the response signal decreases successively. Figure 2 (B) shows the kinetic test results of thioflavin T on the depolymerization of Aβ fibers by forsythiaside A at different concentrations. Figure 2 (C) shows the results of the kinetic test of Thioflavin T of different concentrations of Forsythiaside A inhibiting the aggregation of Aβ induced by seeds. Figure 2 (D) in the figure shows the kinetic test results of Thioflavin T on the inhibition of Aβ42 aggregation by different concentrations of Forsythiaside A. Figure 2 In (A) to (D), as the concentration of forsythiaside A added increases, the response signal intensity decreases successively.
[0069] refer to Figure 2 It can be seen that forsythiaside A can inhibit the aggregation of Aβ40 in a concentration-dependent manner. 5μM, 25μM and 50μM forsythiaside A can reduce the platform thioflavin T signal by about 54%, 79% and 85%, respectively.
[0070] To verify the inhibitory effect of forsythiaside A, dynamic light scattering experiments were subsequently performed to evaluate the size of Aβ40 aggregates in the absence or presence of forsythiaside A. A 5 μM Aβ40 solution was incubated alone at 37°C, 1100 rpm for two days as a control, and particles of about 1000 nm were observed after the incubation. After adding 5 (1:1), 10 (1:2), 25 (1:5), and 50 μM (1:10) forsythiaside A and incubating together, the particle size was observed again, referring to Figure 3 In A, almost no particles larger than 100 nm were found, indicating that forsythiaside A effectively inhibited the formation of larger Aβ40 aggregates. Figure 3 In B, after incubating preformed Aβ40 fibrils with 50 μM forsythiaside A at 37°C and 1100 rpm for 2 days, it was found that the size of Aβ40 aggregates was greatly reduced to about 100 nm.
[0071] Circular dichroism was then performed using NaF buffer consisting of 10 mM sodium phosphate and 150 mM NaF (pH 7.4). CD spectra were recorded using a Chirascan circular dichroism spectrometer. Forsythiaside A was dissolved in NaF buffer at a concentration of 1 mM. 100 μM Aβ40 in 6 mM NaOH was diluted to 10 μM in NaF buffer and incubated for 2 days at 37 °C with continuous shaking at 1100 rpm in a metal bath with different concentrations or without Forsythiaside A. The final volume of the sample was 1000 μL for circular dichroism analysis.
[0072] Circular dichroism spectroscopy was used to analyze the secondary structure of Aβ40 aggregates in the absence or presence of different concentrations of forsythiaside A. In order to obtain a strong primary color spectral signal, a quartz cuvette was used for testing. Preformed 10μAβ40 fibrils were incubated with 10μM or 50μM forsythiaside A for 2 days, and then their circular dichroism spectra were obtained.
[0073] Figure 3 A and B in FIG. 1 show the number distribution (ordinate, Number distribution, %) of particles of different particle sizes (abscissa, Size, d.nm). Figure 3C in the figure shows the circular dichroism of different samples. The newly dissolved Aβ40 (Aβmonomer) shows a negative peak at a wavelength of about 198nm, while the Aβ40 fibril has a typical β-folded structure with a negative peak at about 218nm. When Aβ40 was incubated with 10μM (1:1ForA) or 50μM (1:5ForA) forsythiaside A for 2 days, the negative peak at 218nm decreased, indicating that the β-folded structure was reduced. At the same time, when the preformed 10μAβ40 fibrils were incubated with 10μM or 50μM forsythiaside A for 2 days, the negative peak at 218nm decreased, indicating that forsythiaside A may depolymerize the preformed Aβ40 fibrils. Figure 3 D in the figure shows the content of β-sheet in different samples. By comparison, the β-sheet content of the samples incubated with Aβ40 fibrils and 10μM (1:1ForA) or 50μM (1:5ForA) Forsythiaside A was significantly reduced. Referring to the β-sheet content of Aβ monomer, it can be seen that the β-sheet content after adding Forsythiaside A is similar to that of Aβ monomer, indicating that aggregation is almost completely inhibited.
[0074] Cytotoxicity test was then performed. A 5 μM Aβ40 solution was incubated for 1 day without or with different concentrations of forsythiaside A. The samples were then diluted 10-fold with serum-free medium and incubated with N2a cells for 24 h. Cell viability of different groups was determined using the Cell Counting Kit-8 (CCK8). Cytotoxicity test results Figure 4 As shown in Figure A, forsythiaside A effectively reduced the cytotoxicity of Aβ. When N2a cells were incubated with Aβ40 solution alone, the cell viability was about 56%, while the cell viability was about 96% when incubated with a 1:5 concentration mixed solution of forsythiaside A.
[0075] A 5 μM Aβ40 solution was incubated alone for 2 days to obtain preformed Aβ40 fibrils. Then, different concentrations of forsythiaside A were added to the fibril samples and incubated for another 2 days. Then, the samples were diluted 10 times and added to N2a cells and incubated together using the above method. Finally, the CCK-8 method was used to evaluate the cytotoxicity of different samples. Figure 4 As shown in Figure B, different concentrations of forsythiaside A can reduce cytotoxicity, so forsythiaside A can effectively reduce the cytotoxicity of pre-formed Aβ40 fibrils, indicating that the depolymerized Aβ species is harmless to N2a cells.
[0076] In summary, it has been verified that Forsythiaside A has a good effect in alleviating / inhibiting Aβ aggregation and has low cytotoxicity. Therefore, it has good potential for preparing drugs for preventing and / or alleviating the insoluble accumulation of Aβ protein, inhibitors for inhibiting Aβ aggregation, drugs for preventing and / or treating cognitive impairment diseases, and drugs for preventing and / or treating Alzheimer's disease.
[0077] Since transgenic Caenorhabditis elegans expressing Aβ species have long been used as an animal model for screening and verifying anti-AD drugs, the present application conducted a transgenic Caenorhabditis elegans lifespan experiment on forsythiaside A to further verify its good potential in the preparation of the above-mentioned drugs. In some embodiments, the criterion for the nematode lifespan test can be: after the Aβ40 solution incubated with the natural molecule is added and incubated with the nematodes, the median lifespan of the nematodes increases by no less than 5 days.
[0078] With the gradual expression and aggregation of neurotoxic Aβ species, C. elegans may show some symptoms, including paralysis and shortened lifespan. Molecules that can eliminate Aβ or inhibit Aβ aggregation are expected to extend the lifespan of AD transgenic C. elegans. CL4176 worms expressing human Aβ1-42 were obtained from CGC (Caenorhabditis Genetics Center) and divided into groups. Different groups of CL4176 worms were treated with 0, 10μM and 50μM forsythiaside A, respectively. The survival rate of different groups was recorded every 2 days, and the lifespan of transgenic C. elegans was investigated. Figure 5 As shown, when incubated alone, the maximum lifespan of CL4176 nematodes was 24 days. After adding 10 μM and 50 μM forsythiaside A, the maximum lifespan of CL4176 nematodes increased to 36 and 38 days, respectively.
[0079] The antibody PA5 purchased from Thermo Fisher (Catalog #PA5-77843) selectively binds to Aβ fibrils. The antibody 4G8 that recognizes the middle region of Aβ was used as a control to confirm the presence of Aβ. Aβ40 was incubated with or without forsythiaside A for different times and spotted on two nitrocellulose membranes. The two membranes were then stained with PA5 and 4G8, respectively. Reference Figure 6 As can be seen from the A in the sample, Aβ rapidly formed fibrils when incubated alone (PA5, upper lane, Aβ), while the addition of forsythiaside A to the sample (PA5, lower lane, Aβ+1:5ForA) inhibited the formation of fibrils. After incubation with forsythiaside A for 24-48 hours, no detectable PA5-reactive Aβ fibrils were found by dot blotting, verifying that forsythiaside A can inhibit the formation of Aβ40 fibrils. In addition, we also incubated the preformed Aβ40 fibrils with forsythiaside A for different periods of time and monitored the consistency of the fibrils, referring to Figure 6As shown in B, Forsythiaside A showed a good inhibitory effect 3 hours after addition.
[0080] In addition, the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of technical features indicated. Therefore, a feature defined as "first" or "second" may explicitly or implicitly include one or more of the features. In the description of the present disclosure, the meaning of "plurality" is two or more, unless otherwise clearly and specifically defined.
[0081] In the present disclosure, unless otherwise clearly specified and limited, the terms "installed", "connected", "connected", "fixed" and the like should be understood in a broad sense, for example, it can be a fixed connection, a detachable connection, or an integral connection; it can be a mechanical connection, an electrical connection, or a communication; it can be a direct connection, or an indirect connection through an intermediate medium, it can be the internal connection of two elements or the interaction relationship between two elements. For ordinary technicians in this field, the specific meanings of the above terms in the present disclosure can be understood according to specific circumstances.
[0082] In the present disclosure, unless otherwise clearly specified and limited, a first feature being “above” or “below” a second feature may include that the first and second features are in direct contact, or may include that the first and second features are not in direct contact but are in contact through another feature between them. Moreover, a first feature being “above”, “above”, and “above” a second feature includes that the first feature is directly above and obliquely above the second feature, or simply indicates that the first feature is higher in level than the second feature. A first feature being “below”, “below”, and “below” a second feature includes that the first feature is directly above and obliquely above the second feature, or simply indicates that the first feature is lower in level than the second feature.
[0083] The disclosure above provides many different embodiments or examples to implement different structures of the present disclosure. In order to simplify the present disclosure, the components and settings of specific examples are described above. Of course, they are only examples, and the purpose is not to limit the present disclosure. In addition, the present disclosure can repeat reference numbers and / or reference letters in different examples, and this repetition is for the purpose of simplification and clarity, which itself does not indicate the relationship between the various embodiments and / or settings discussed.
[0084] The above are only specific embodiments of the present disclosure, but the protection scope of the present disclosure is not limited thereto. Any technician familiar with the technical field can easily think of various changes or substitutions within the technical scope disclosed in the present disclosure, which should be included in the protection scope of the present disclosure. Therefore, the protection scope of the present disclosure should be based on the protection scope of the claims.
Claims
1. Use of forsythiaside A in the preparation of a medicament for preventing and / or alleviating the insoluble accumulation of Aβ protein.
2. Use of forsythiaside A in the preparation of inhibitors for inhibiting Aβ aggregation.
3. Use of Forsythiaside A in the preparation of drugs for preventing and / or treating diseases of cognitive impairment.
4. Use of forsythiaside A in the preparation of a drug for preventing and / or treating Alzheimer's disease.
5. A method for screening active ingredients in a drug, the method comprising: Retrieving and screening natural molecules in a database, wherein the molecular weight of the natural molecules is no greater than 2000; Performing molecular docking between the natural molecule and the Aβ fiber target by using Gold software, and performing simulation scoring on the molecular docking, and selecting the natural molecules with scores exceeding 80 to form a potential active component set; The molecules of the potential active component set are tested for Aβ aggregation inhibition effect to determine one or more active components, The Aβ aggregation inhibition effect test includes at least one of a Thioflavin T kinetic test, an Aβ aggregate dynamic light scattering test, a circular dichroism test, a cytotoxicity test, and a nematode lifespan test. The drug is the drug or inhibitor according to any one of claims 1 to 4.
6. The method according to claim 5, characterized in that The database includes the Selleck database, and the searching and screening includes selecting natural products of traditional Chinese medicine in the database.
7. The method according to claim 6, characterized in that The simulation scoring of the molecular docking includes: Through molecular docking, the binding activity of the natural molecule and the target is predicted and a simulation score is performed. The target is a target related to the inhibition and / or disaggregation of Aβ aggregates, and the target includes the Aβ fiber end and the Aβ fiber surface. The simulation score includes analyzing the characteristics of the natural molecule and the target, and simulating the binding mode of the natural molecule and the target.
8. The method according to claim 6 or 7, characterized in that: The potential active component set includes: itraconazole, thymopentin, diammonium glycyrrhizinate, forsythiaside B, angloside C, barisenoside A, neferine, forsythiaside A, and steviol glycoside.
9. The method according to claim 8, characterized in that The Aβ aggregation inhibition effect test includes: (1) dissolving the natural molecules in the potential active component set in DMSO to prepare solutions with a concentration of 5-15 mM, and performing thioflavin T kinetic tests on them respectively; (2) selecting the natural molecule with the largest reduction in Thioflavin T signal in the Thioflavin T kinetic test, and continuing to perform Aβ40 aggregate dynamic light scattering test and circular dichroism test; (3) If the Aβ40 aggregate dynamic light scattering test and circular dichroism test results of the natural molecule meet the standards, the cytotoxicity test and nematode lifespan test are continued; if one of the Aβ40 aggregate dynamic light scattering test and circular dichroism test results do not meet the standards, the natural molecule with the second largest reduction in the Thioflavin T signal in the Thioflavin T kinetic test is selected, and the Aβ40 aggregate dynamic light scattering test and circular dichroism test are continued; (4) If the cytotoxicity test and the nematode lifespan test meet the standards, the natural molecule is determined to be the active component. If the cytotoxicity test does not meet the standards, the natural molecule with the second largest reduction in the thioflavin T signal in the thioflavin T kinetic test is selected to continue the test in step (2) until the Aβ40 aggregate dynamic light scattering test and the circular dichroism test of the selected natural molecule meet the standards, and the cytotoxicity test and the nematode lifespan test meet the standards.
10. The method according to claim 9, characterized in that The standard for the Aβ40 aggregate dynamic light scattering test effect to meet the standard is: after incubation in the presence of the natural molecule, the particle size of the Aβ40 aggregate particles is reduced by not less than 80%; The standard for the circular dichroism test effect to meet the standard is that after incubation treatment under the condition of the presence of the natural molecule, the absolute value of the peak intensity of the circular dichroism characteristic peak of the Aβ40 aggregate is reduced by more than 50%; The cytotoxicity test meets the standard that: after the Aβ40 solution incubated with the natural molecule is incubated with N2a cells, the survival rate of N2a cells is not less than 70%; The criterion for the nematode lifespan test to pass the test is that after the natural molecule is added and the Aβ40 solution that has been incubated is incubated with the nematodes, the median lifespan of the nematodes increases by no less than 5 days.
